Current/ Expected Orderbook/ Pending Orders?

The company currently has approximately 1,500 beds under execution. These new capacity additions are expected to be operational by March 2028. This expansion will increase total bed capacity to 5,460 by that time. Total planned capex for the next two years is around INR 500 crores. Recent investments include Panchkula Greenfield construction, and acquisitions/commissioning of Bathinda, Agra, and Narela hospitals. The company is aggressively looking for further expansion opportunities and is open to acquisitions or Greenfield projects, focusing on strategic, low-capex growth. Funding is primari

Any current/future new fundraising through debt or equity?

The company currently has sufficient funds, including close to INR314 crores in fixed deposits and about INR100 crores in bank accounts. Operating cash flow is strong (close to INR330 crores annually), supporting internal funding capabilities. For the near term, minor debt may be considered but no major debt raising is planned. The company emphasizes maintaining low capex and financial discipline to avoid heavy borrowing. For large acquisitions or expansion opportunities, the company is open to raising debt if found lucrative. No explicit mention of planned equity fundraising was made in the p

Any current/future capex/capital investment/strategic investment?

Park Medi World is undertaking a significant bed expansion with a capex of about INR 34 lakhs per bed, aiming to increase capacity to 5,460 beds by FY’28 and potentially doubling to over 10,000 beds by FY’33. Current capex underway includes: - Panchkula: 350 beds with INR 125 crores invested. - Delhi Narela: 200 beds with total planned capex INR 80 crores (INR 55 crores spent). - Kanpur: Additional INR 30 crores planned. Capex planned for FY’27 is about INR 55 crores; for FY’28, approximately INR 250 crores. Future capex of close to INR 500 crores projected for next two years, funded

Future growth expectations in sales/revenue/volumes?

Park Medi World plans significant bed expansion: adding 1,850 beds currently under execution, with 350 beds added at Panchkula and 200 beds at Delhi Narela. Capex guidance: INR55 crores planned for the current year and approximately INR250 crores in FY28 for adding 1,000 beds. Long-term vision (FY28 to FY33): Plans to double bed capacity from 5,460 to over 10,000 beds. Expansion focus on Tier-2 and Tier-3 cities due to growing demand for affordable, high-quality healthcare, reducing patient outflow to metros. Continued increase in government insurance payor mix expected to stabilize around 70%

Future growth expectations in earnings/operating earnings/profits/EPS?

The company plans significant bed capacity expansion, aiming to increase beds from 5,460 in FY’28 to over 10,000 by FY’33, potentially doubling capacity. Capex for FY’28 is expected around INR 250 crores, focused on adding 1,000 beds; no major new debt anticipated. Revenue growth is supported by expanding into Tier-2 and Tier-3 cities, meeting strong demand for affordable, high-quality healthcare. ARPOB (average revenue per occupied bed) growth is expected around 5-6%, driven by improved case mix and high-end procedures. Operating efficiencies and low capex per bed (~INR 34 lakhs) help maintai

IN US

Sale is live|00:00:00left today

Park Medi World LtdQ1 FY26Healthcare Services

Park Medi World Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹287P/E: 40.9Market Cap: ₹10.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Park Medi World plans significant bed expansion: adding 1,850 beds currently under execution, with 350 beds added at Panchkula and 200 beds at Delhi Narela.
→Capex guidance: INR55 crores planned for the current year and approximately INR250 crores in FY28 for adding 1,000 beds.
→Long-term vision (FY28 to FY33): Plans to double bed capacity from 5,460 to over 10,000 beds.
→Expansion focus on Tier-2 and Tier-3 cities due to growing demand for affordable, high-quality healthcare, reducing patient outflow to metros.
→Continued increase in government insurance payor mix expected to stabilize around 70%.
→Revenue growth drivers include case mix improvement towards higher acuity specialties and operational efficiencies.
→No major debt funding planned; capex funded from internal resources to ensure sustainable growth.

Margin guidance

Category 3

→The company plans significant bed capacity expansion, aiming to increase beds from 5,460 in FY’28 to over 10,000 by FY’33, potentially doubling capacity.
→Capex for FY’28 is expected around INR 250 crores, focused on adding 1,000 beds; no major new debt anticipated.
→Revenue growth is supported by expanding into Tier-2 and Tier-3 cities, meeting strong demand for affordable, high-quality healthcare.
→ARPOB (average revenue per occupied bed) growth is expected around 5-6%, driven by improved case mix and high-end procedures.
→Operating efficiencies and low capex per bed (~INR 34 lakhs) help maintain profitability despite inflationary pressures.
→Government insurance mix (~70%) remains stable, supporting steady collections and reduced receivable days (currently 129 days).
→Overall, the company anticipates sustainable long-term profitability growth through strategic expansions and operational excellence.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company currently has sufficient funds, including close to INR314 crores in fixed deposits and about INR100 crores in bank accounts.
→Operating cash flow is strong (close to INR330 crores annually), supporting internal funding capabilities.
→For the near term, minor debt may be considered but no major debt raising is planned.
→The company emphasizes maintaining low capex and financial discipline to avoid heavy borrowing.
→For large acquisitions or expansion opportunities, the company is open to raising debt if found lucrative.
→No explicit mention of planned equity fundraising was made in the provided excerpts.
→Overall, expansion and acquisitions are expected to be funded primarily through internal accruals and existing cash reserves, with selective, small debt as needed.

Order book

Yes

→The company currently has approximately 1,500 beds under execution.
→These new capacity additions are expected to be operational by March 2028.
→This expansion will increase total bed capacity to 5,460 by that time.
→Total planned capex for the next two years is around INR 500 crores.
→Recent investments include Panchkula Greenfield construction, and acquisitions/commissioning of Bathinda, Agra, and Narela hospitals.
→The company is aggressively looking for further expansion opportunities and is open to acquisitions or Greenfield projects, focusing on strategic, low-capex growth.
→Funding is primarily from existing cash reserves and operational cash flow; small debt may be considered but is not a major reliance.

Capex plans

Yes

→Park Medi World is undertaking a significant bed expansion with a capex of about INR 34 lakhs per bed, aiming to increase capacity to 5,460 beds by FY’28 and potentially doubling to over 10,000 beds by FY’33.
→Current capex underway includes:
→ - Panchkula: 350 beds with INR 125 crores invested.
→ - Delhi Narela: 200 beds with total planned capex INR 80 crores (INR 55 crores spent).
→ - Kanpur: Additional INR 30 crores planned.
→Capex planned for FY’27 is about INR 55 crores; for FY’28, approximately INR 250 crores.
→Future capex of close to INR 500 crores projected for next two years, funded primarily through internal accruals and cash reserves, with minor debt if needed.
→Strategic investments focus on nearby hospitals (within 40-50 km) to create operational synergies, keeping capex and opex controlled.

How does Park Medi World Ltd rank vs peers in Healthcare Services?

Pro feature

1Park Medi World Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Park Medi World Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio